company background image

Aytu BioPharma NasdaqCM:AYTU Stock Report

Last Price


Market Cap







28 Sep, 2022


Company Financials +
AYTU fundamental analysis
Snowflake Score
Future Growth1/6
Past Performance0/6
Financial Health2/6

AYTU Stock Overview

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally.

Aytu BioPharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aytu BioPharma
Historical stock prices
Current Share PriceUS$0.19
52 Week HighUS$2.99
52 Week LowUS$0.18
1 Month Change-17.98%
3 Month Change-72.30%
1 Year Change-93.13%
3 Year Change-98.29%
5 Year Change-99.98%
Change since IPO-100.00%

Recent News & Updates

Sep 27

Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95M

Aytu BioScience press release (NASDAQ:AYTU): FQ4 GAAP EPS of -$0.49 misses by $0.12. Revenue of $27.45M (+16.9% Y/Y) beats by $1.95M. Cash and cash equivalents at the end of the fiscal year ended June 30, 2022 were $19.4 million. Subsequent to the end of the year, the Company raised $10.0 million in gross proceeds in a registered public offering. Prescription segment Adjusted EBITDA was a positive $1.1 million, while Consumer Health was $(2.1) million resulting in a combined Adjusted EBITDA of $(1.0) million for the Company's commercial business. This compares to Adjusted EBITDA of $(5.5) million for the Prescription segment and $(2.7) million for the Consumer Health segment in Q4 2021, resulting in a combined Adjusted EBITDA of $(8.2) million for the Company's commercial business. Shares +5.26%.

Sep 14

Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorder

Aytu BioPharma (NASDAQ:AYTU) announced on Wednesday the addition of a fourth patent for AR101/Enzastaurin to treat Vascular Ehlers-Danlos Syndrome, rare genetic disorder treatment. The patent has an expiry date of September 2041. The company expects to advance the PREVEnt Trial in VEDS for AR101 and dose the first patient by early 2023. "Adding this fourth patent to the portfolio deepens and broadens the intellectual property surrounding AR101/Enzastaurin for the treatment of inherited vascular disorders, including VEDS, for which we are advancing AR101 as an initial indication," the company said. Vascular Ehlers-Danlos syndrome (vEDS) is the most severe type of a hereditary disorder of the connective tissue. (AYTU) had risen 3.3% before the bell.

Aug 16

Aytu gets US patent for AR101/Enzastaurin for circulatory system disorders

Aytu BioPharma (NASDAQ:AYTU) said the U.S. Patent and Trademark Office issued a patent, a first for AR101/Enzastaurin. The U.S. patent No. 11,273,148 titled 'Targeted Epigenetic Therapy for Inherited Aortic Aneurism Condition,' covers methods for the targeted epigenetic therapy of inherited aortic aneurysm and other diseases with altered regulation of TGFβ genes, including Ehlers-Danlos Syndrome, the company said in an Aug. 16 press release. Aytu added that it was the first issued patent supporting the portfolio and expires in August of 2038, if not extended. "This issued patent underpins the broad potential clinical application across numerous inherited vascular disorders, including vascular Ehlers-Danlos Syndrome ("VEDS"), for which we are advancing AR101 as an initial indication. We expect to progress the PREVEnt Trial in VEDS for AR101 and dose the first patient by early 2023," said Aytu CEO Josh Disbrow. AYTU +0.59% to $0.29 premarket Aug. 16

Shareholder Returns

AYTUUS PharmaceuticalsUS Market

Return vs Industry: AYTU underperformed the US Pharmaceuticals industry which returned 4.2% over the past year.

Return vs Market: AYTU underperformed the US Market which returned -22.1% over the past year.

Price Volatility

Is AYTU's price volatile compared to industry and market?
AYTU volatility
AYTU Average Weekly Movement18.8%
Pharmaceuticals Industry Average Movement11.5%
Market Average Movement6.9%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: AYTU is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.

Volatility Over Time: AYTU's weekly volatility has increased from 13% to 19% over the past year.

About the Company

2015164Josh Disbrow

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; and Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency.

Aytu BioPharma Fundamentals Summary

How do Aytu BioPharma's earnings and revenue compare to its market cap?
AYTU fundamental statistics
Market CapUS$11.93m
Earnings (TTM)-US$110.17m
Revenue (TTM)US$96.67m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AYTU income statement (TTM)
Cost of RevenueUS$44.39m
Gross ProfitUS$52.28m
Other ExpensesUS$162.46m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-1.76
Gross Margin54.08%
Net Profit Margin-113.97%
Debt/Equity Ratio39.1%

How did AYTU perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is AYTU undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 5/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AYTU?

Other financial metrics that can be useful for relative valuation.

AYTU key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.1x
Enterprise Value/EBITDA-0.4x
PEG Ration/a

Price to Sales Ratio vs Peers

How does AYTU's PS Ratio compare to its peers?

AYTU PS Ratio vs Peers
The above table shows the PS ratio for AYTU vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average1.4x
CURR CURE Pharmaceutical Holding
BMMJ Body and Mind
UNRV Unrivaled Brands
AYTU Aytu BioPharma

Price-To-Sales vs Peers: AYTU is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (1.4x).

Price to Earnings Ratio vs Industry

How does AYTU's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Sales vs Industry: AYTU is good value based on its Price-To-Sales Ratio (0.1x) compared to the US Pharmaceuticals industry average (2.7x)

Price to Sales Ratio vs Fair Ratio

What is AYTU's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AYTU PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.1x
Fair PS Ratio2.2x

Price-To-Sales vs Fair Ratio: AYTU is good value based on its Price-To-Sales Ratio (0.1x) compared to the estimated Fair Price-To-Sales Ratio (2.2x).

Share Price vs Fair Value

What is the Fair Price of AYTU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AYTU ($0.19) is trading below our estimate of fair value ($7.48)

Significantly Below Fair Value: AYTU is trading below fair value by more than 20%.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Future Growth

How is Aytu BioPharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score


Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AYTU is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AYTU is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AYTU is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AYTU's revenue (8.7% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: AYTU's revenue (8.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if AYTU's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has Aytu BioPharma performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: AYTU is currently unprofitable.

Growing Profit Margin: AYTU is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: AYTU is unprofitable, and losses have increased over the past 5 years at a rate of 44.6% per year.

Accelerating Growth: Unable to compare AYTU's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AYTU is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).

Return on Equity

High ROE: AYTU has a negative Return on Equity (-239.03%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Aytu BioPharma's financial position?

Financial Health Score


Financial Health Score 2/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: AYTU's short term assets ($59.9M) do not cover its short term liabilities ($64.4M).

Long Term Liabilities: AYTU's short term assets ($59.9M) exceed its long term liabilities ($27.1M).

Debt to Equity History and Analysis

Debt Level: AYTU has more cash than its total debt.

Reducing Debt: Insufficient data to determine if AYTU's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AYTU has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: AYTU has less than a year of cash runway if free cash flow continues to reduce at historical rates of 12.6% each year

Discover healthy companies


What is Aytu BioPharma current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Aytu BioPharma Dividend Yield vs Market
How does Aytu BioPharma dividend yield compare to the market?
SegmentDividend Yield
Company (Aytu BioPharma)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.6%
Industry Average (Pharmaceuticals)2.5%
Analyst forecast in 3 Years (Aytu BioPharma)n/a

Notable Dividend: Unable to evaluate AYTU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AYTU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AYTU's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AYTU's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as AYTU has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Josh Disbrow (47 yo)





Mr. Joshua R. Disbrow, also known as Josh, is Chairman of the Board at Aytu Biopharma, Inc. (formerly known as Aytu BioScience, Inc.) since July 2016 and serves as its Chief Executive Officer. He serves as...

CEO Compensation Analysis

Josh Disbrow's Compensation vs Aytu BioPharma Earnings
How has Josh Disbrow's remuneration changed compared to Aytu BioPharma's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a


Mar 31 2022n/an/a


Dec 31 2021n/an/a


Sep 30 2021n/an/a


Jun 30 2021US$6mUS$545k


Mar 31 2021n/an/a


Dec 31 2020n/an/a


Sep 30 2020n/an/a


Jun 30 2020US$2mUS$608k


Mar 31 2020n/an/a


Dec 31 2019n/an/a


Sep 30 2019n/an/a


Jun 30 2019US$1mUS$330k


Mar 31 2019n/an/a


Dec 31 2018n/an/a


Sep 30 2018n/an/a


Jun 30 2018US$606kUS$303k


Mar 31 2018n/an/a


Dec 31 2017n/an/a


Sep 30 2017n/an/a


Jun 30 2017US$1mUS$250k


Mar 31 2017n/an/a


Dec 31 2016n/an/a


Sep 30 2016n/an/a


Jun 30 2016US$1mUS$250k


Compensation vs Market: Josh's total compensation ($USD6.20M) is above average for companies of similar size in the US market ($USD784.47K).

Compensation vs Earnings: Josh's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: AYTU's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

Experienced Board: AYTU's board of directors are considered experienced (6.3 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of AYTU?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,866,8893.0%
VC/PE Firms3,400,0005.4%
General Public52,740,65584.5%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 126.6%.

Top Shareholders

Top 25 shareholders own 15.35% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
Heights Capital Management, Inc.
The Vanguard Group, Inc.
1,090,778$208.4k50.96%no data
Renaissance Technologies LLC
1,055,782$201.8k37.93%no data
Joshua Disbrow
897,622$171.5k0%no data
Sabby Management, LLC
BlackRock, Inc.
482,611$92.2k-11.59%no data
Geode Capital Management, LLC
252,147$48.2k-2.66%no data
Michael Macaluso
208,079$39.8k0%no data
John Donofrio
206,074$39.4k1.48%no data
Gary Cantrell
204,089$39.0k0%no data
Carl Dockery
204,072$39.0k0.49%no data
Millennium Management LLC
174,797$33.4k-34.27%no data
Wilcoxson Wealth Management
109,699$21.0k-0.08%no data
Mark Oki
100,000$19.1k0%no data
State Street Global Advisors, Inc.
97,684$18.7k0%no data
Susquehanna Fundamental Investments, LLC
53,530$10.2k0%no data
Northern Trust Global Investments
48,132$9.2k-1.03%no data
Tower Research Capital LLC
41,621$8.0k51.77%no data
Two Sigma Investments, LP
40,871$7.8k0%no data
PGIM, Inc.
40,750$7.8k0%no data
Group One Trading LP, Asset Management Arm
40,590$7.8k378.09%no data
Gerald McLaughlin
31,401$6.0k0%no data
Two Sigma Advisers, LP
27,200$5.2k14.77%no data
Morgan Stanley, Investment Banking and Brokerage Investments
25,486$4.9k-50.24%no data
BBVA Asset Management, S.A., S.G.I.I.C.
20,076$3.8k0%no data

Company Information

Aytu BioPharma, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: Aytu BioPharma, Inc.
  • Ticker: AYTU
  • Exchange: NasdaqCM
  • Founded: 2015
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$11.931m
  • Shares outstanding: 62.43m
  • Website:

Number of Employees


  • Aytu BioPharma, Inc.
  • 373 Inverness Parkway
  • Suite 206
  • Englewood
  • Colorado
  • 80112
  • United States


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AYTUNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDApr 2015
AY2DB (Deutsche Boerse AG)YesCommon StockDEEURApr 2015
0A8MLSE (London Stock Exchange)YesCommon StockGBUSDApr 2015

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/28 00:00
End of Day Share Price2022/09/28 00:00
Annual Earnings2022/06/30

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.